🔎 Trials Near Me

Pradžia › Plaučių vėžys › Mičiganas

Plaučių vėžys klinikiniai tyrimai Mičiganas

44 tyrimai dėl Plaučių vėžys ieško dalyvių vietose Mičiganas.

Miestai Mičiganas

Oficialus tyrimo tekstas (anglų kalba)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Bronson Battle Creek, Battle Creek
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • ir dar 50
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT04267848

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • MyMichigan Medical Center Gratiot, Alma
  • MyMichigan Medical Center Alpena, Alpena
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • ir dar 68
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 40 iki 75 · Visoms lytims · Atnaujinta 2026-10-02 · NCT05334069

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

  • Bronson Battle Creek, Battle Creek
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
  • ir dar 20
Renkami dalyviai3 fazė
Amžius 70 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT06096844

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health Medical Center - Brighton, Brighton
  • ir dar 27
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT04181060

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • University of Michigan Rogel Cancer Center, Ann Arbor
  • Bronson Battle Creek, Battle Creek
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • ir dar 38
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT06498635

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • Trinity Health Ann Arbor Hospital, Ann Arbor
  • Karmanos Cancer Institute, Detroit
  • Henry Ford Health, Detroit
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-29 · NCT06881784

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Corewell Health - Butterworth Hospital, Grand Rapids
  • Corewell Health - Lemmen Holton Cancer Pavilion, Grand Rapids
  • Corewell Health - Research Specimen Processing Area, Grand Rapids
  • ir dar 2
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06758401

A Registry for People With Lung Cancer

  • University of Michigan (Data Collection Only), Ann Arbor
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-24 · NCT06424327

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  • Local Institution - 0418, Ann Arbor
  • Local Institution - 0405, Detroit
  • Local Institution - 0420, Traverse City
Renkami dalyviai2/3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT07063745

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • START Midwest, Grand Rapids
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT06128551

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

  • University of Michigan Medical School Rogel Cancer Center, Ann Arbor
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-21 · NCT07629960

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

  • START Midwest, Grand Rapids
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-17 · NCT07349537

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  • South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-16 · NCT05786924

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Karmanos Cancer Institiute, Detroit
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-10 · NCT06293898

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • University of Michigan, Ann Arbor
  • The Cancer & Hematology Centers, Grand Rapids
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-08 · NCT06119581

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  • South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-04 · NCT06400472

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

  • Henry Ford Cancer - Detroit, Detroit
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-03 · NCT06343402

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Henry Ford Cancer Institute-Downriver, Brownstown
  • Henry Ford Health Center - Brownstown, Brownstown
  • Henry Ford Health Center - Chesterfield, Chesterfield
  • ir dar 13
Renkami dalyviaiLaukiami sveiki savanoriai
Amžius nuo 45 iki 75 · Visoms lytims · Atnaujinta 2026-09-02 · NCT06995898

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

  • University of Michigan, Ann Arbor
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-19 · NCT07499674

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

  • Wayne State University/Karmanos Cancer Institute, Detroit
  • Weisberg Cancer Treatment Center, Farmington Hills
  • McLaren Cancer Institute-Flint, Flint
  • ir dar 1
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-17 · NCT06500481

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • McLaren Cancer Institute-Bay City, Bay City
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • ir dar 41
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-17 · NCT05624996

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • Karmanos Cancer Institute, Detroit
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-11 · NCT05592626

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

  • START - Midwest, Grand Rapids
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-05 · NCT07444814

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • Henry Ford Cancer Institute, Detroit
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-29 · NCT04198766

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

  • Henry Ford Cancer- Detroit, Detroit
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-28 · NCT07339059

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  • Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-30 · NCT06162221

Gilteritinib for the Treatment of ALK NSCLC

  • University of Michigan Comprehensive Cancer Center, Ann Arbor
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-26 · NCT06225427

Prediction Augmented Screening Initiative

  • VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
Renkami dalyviai
Amžius nuo 50 iki 80 · Visoms lytims · Atnaujinta 2026-06-26 · NCT06538636

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

  • Karmanos Cancer Institute, Detroit
Renkami dalyviai2 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-06-26 · NCT04614103

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health Medical Center - Brighton, Brighton
  • ir dar 19
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-03 · NCT05642572

A Study of ZW251 in Participants With Advanced Solid Tumors

  • START Midwest, Grand Rapids
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-07 · NCT07164313

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health Medical Center - Brighton, Brighton
  • ir dar 14
Renkami dalyviai2 fazė
18 Minutes · Visoms lytims · Atnaujinta 2026-05-05 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
  • ir dar 7
Renkami dalyviai2/3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-05 · NCT06616584

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

  • University of Michigan, Ann Arbor
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-22 · NCT07020221

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

  • Karmanos Cancer Institute, Detroit
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-18 · NCT06244771

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

  • VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-02-19 · NCT02984761

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

  • VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-01-27 · NCT05467748

A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients

  • University of Michigan Comprehensive Cancer Center, Ann Arbor
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-01-21 · NCT07291414

Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.